SEC Filing Summary: Trovagene, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. on November 19, 2015, reporting events occurring on November 13, 2015. The registrant is a Delaware corporation headquartered in San Diego, California. Note: The input metadata references "Cardiff Oncology, Inc.," but the filing text explicitly identifies the registrant as "Trovagene, Inc."
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance data.
Material Changes
The primary material change reported is the departure of a director:
- Carl Feldbaum resigned as a director of Trovagene, Inc. on November 13, 2015.
- The stated reason for resignation is to pursue other professional opportunities.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary on operations, risks, contingencies, or unusual items beyond the director resignation.
Key Facts for Investor Verification
- Verify the current composition of the Board of Directors following Carl Feldbaum's resignation.
- Confirm whether the resignation of Mr. Feldbaum impacts any ongoing strategic initiatives or committee assignments.
- Review subsequent filings to determine if a replacement director was appointed.